[{"orgOrder":0,"company":"Fera Pharmaceuticals, LLC","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Naproxcinod","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fera Pharmaceuticals, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fera Pharmaceuticals, LLC \/ Nicox","highestDevelopmentStatusID":"1","companyTruncated":"Fera Pharmaceuticals, LLC \/ Nicox"},{"orgOrder":0,"company":"Fera Pharmaceuticals, LLC","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naproxcinod","moa":"COX","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Fera Pharmaceuticals, LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Fera Pharmaceuticals, LLC \/ Nicox","highestDevelopmentStatusID":"4","companyTruncated":"Fera Pharmaceuticals, LLC \/ Nicox"}]

Find Clinical Drug Pipeline Developments & Deals by Fera Pharmaceuticals, LLC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Naproxcinod, a Cyclooxygenase-Inhibiting Nitric Oxide (NO)-Donating (CINOD) naproxen, is a non-steroidal anti-inflammatory product candidate engineered to release NO and naproxen, originally discovered and developed by Nicox.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 30, 2021

                          Lead Product(s) : Naproxcinod

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Nicox SA

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Naproxcinod is a nonsteroidal anti-inflammatory product candidate engineered to release NO and naproxen, originally discovered and developed by Nicox. Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 11, 2020

                          Lead Product(s) : Naproxcinod

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Nicox SA

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank